Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. (a foreign private issuer) is dated March 23, 2022, covering the month of March 2022. The report serves to update investors on specific changes in the company's management structure.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the appointment of Mr. Yaron Eldad as Chief Financial Officer (CFO), effective April 1, 2022. He will replace Ms. Dorit Kreiner, whose departure was extended until March 31, 2022. Mr. Eldad brings 25 years of financial experience in public and private technology and biotechnology sectors, including previous CFO roles at Yamba Group Int. Ltd., Recoly NV, and e-Sim Ltd.
Guidance, Outlook, and Risks
The filing does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is strictly limited to the announcement of the executive leadership transition.
Key Facts for Investor Verification
- Mr. Yaron Eldad assumes the role of CFO on April 1, 2022.
- Ms. Dorit Kreiner's tenure as CFO concludes on March 31, 2022.
- Mr. Eldad holds an Executive MBA and an M.A. in law, with prior board service at B.O.S. Better Online Solutions Ltd.
- This report is incorporated by reference into the company's registration statements on Form F-3 and Form S-8.